E-LIB Suche - Ergebnisse für: Arriola, Edurne

1

RET Fusion Testing in Patients With NSCLC: The RETING Study:

Conde, Esther ; Hernandez, Susana ; Rodriguez Carrillo, Jose Luis...
JTO Clinical and Research Reports. 5 (2024) 4 - p. 100653 , 2024

Link: https://doi.org/10.1016/..

2

Consolidation Osimertinib Versus Durvalumab Versus Observat..:

Nassar, Amin H. ; Kim, So Yeon ; Aredo, Jacqueline V....
Journal of Thoracic Oncology. 19 (2024) 6 - p. 928-940 , 2024

Link: https://doi.org/10.1016/..

3

Tumor- and circulating-free DNA methylation identifies clin..:

Heeke, Simon ; Gay, Carl M. ; Estecio, Marcos R....
Cancer Cell. 42 (2024) 2 - p. 225-237.e5 , 2024

Link: https://doi.org/10.1016/..

4

SEOM-GECP Clinical guidelines for diagnosis, treatment and ..:

García-Campelo, Rosario ; Sullivan, Ivana ; Arriola, Edurne...
Clinical and Translational Oncology. 25 (2023) 9 - p. 2679-2691 , 2023

Link: https://doi.org/10.1007/..

5

Correction to: SEOM-GECP Clinical guidelines for diagnosis,..:

García-Campelo, Rosario ; Sullivan, Ivana ; Arriola, Edurne...
Clinical and Translational Oncology. 25 (2023) 9 - p. 2760-2762 , 2023

Link: https://doi.org/10.1007/..

6

Pre-existing tumor host immunity characterization in resect..:

Rocha, Pedro ; Rodrigo, Maite ; Moliner, Laura...
Lung Cancer. 181 (2023) - p. 107257 , 2023

Link: https://doi.org/10.1016/..

7

Feasibility and User Experience of Digital Patient Monitori..:

Arriola, Edurne ; Jaal, Jana ; Edvardsen, Anne...
The Oncologist. 29 (2023) 4 - p. e561-e569 , 2023

Link: https://doi.org/10.1093/..

8

Acquired Mechanisms of Resistance to Osimertinib—The Next C..:

Ríos-Hoyo, Alejandro ; Moliner, Laura ; Arriola, Edurne
Cancers. 14 (2022) 8 - p. 1931 , 2022

Link: https://doi.org/10.3390/..

9

Prognostic Value of Clinical Staging According to TNM in Pa..:

Arriola, Edurne ; Trigo, José Manuel ; Sánchez-Gastaldo, Amparo...
JTO Clinical and Research Reports. 3 (2022) 1 - p. 100266 , 2022

Link: https://doi.org/10.1016/..

10

Addition of Immune Checkpoint Inhibitors to Chemotherapy vs..:

Arriola, Edurne ; González-Cao, María ; Domine, Manuel...
Oncology and Therapy. 10 (2022) 1 - p. 167-184 , 2022

Link: https://doi.org/10.1007/..

11

Comparison of Different Methods for Defining Hyperprogressi..:

Rocha, Pedro ; Ramal, Didac ; Ripoll, Enric...
JTO Clinical and Research Reports. 2 (2021) 1 - p. 100115 , 2021

Link: https://doi.org/10.1016/..

12

CD8 T‐cell‐mediated cerebellitis directed against Purkinje ..:

Hardwick, Marc ; Nolan, Luke ; Nicoll, James A. R....
Neuropathology and Applied Neurobiology. 48 (2021) 2 - p. , 2021

Link: https://doi.org/10.1111/..

13

Plasmatic KRAS Kinetics for the Prediction of Treatment Res..:

Taus, Álvaro ; Camacho, Laura ; Rocha, Pedro...
Archivos de Bronconeumología. 57 (2021) 5 - p. 323-329 , 2021

Link: https://doi.org/10.1016/..

14

CD8 T cell-mediated cerebellitis directed against Purkinje ..:

Hardwick, Marc ; Nolan, Luke ; Nicoll, James...
Journal of the Neurological Sciences. 429 (2021) - p. 118843 , 2021

Link: https://doi.org/10.1016/..

15

Plasmatic KRAS Kinetics for the Prediction of Treatment Res..:

Taus, Álvaro ; Camacho, Laura ; Rocha, Pedro...
Archivos de Bronconeumología (English Edition). 57 (2021) 5 - p. 323-329 , 2021

Link: https://doi.org/10.1016/..